Skip to content

Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence

Bacterial Vaginosis; A Randomized Trial to Reduce Recurrence

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00542074
Enrollment
223
Registered
2007-10-10
Start date
2003-06-30
Completion date
2005-08-31
Last updated
2007-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Vaginosis

Keywords

Bacterial vaginosis, recurrence, male factor

Brief summary

Randomized controlled trial (RCT) to evaluate the effectiveness of applying Purell® (62% ethyl alcohol in emollient gel) to the penis of male partners of women diagnosed with BV for preventing BV recurrence after treatment.

Interventions

OTHERhygienic information plus 62% ethyl alcohol in emollient gel

The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).

OTHERhygienic information

Couples received a brochure with information on control of STI and good hygienic practices.

Sponsors

Fogarty International Center of the National Institute of Health
CollaboratorNIH
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
University of Washington
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Vaginal symptoms * Nugent score \> 6 for vaginal fluid gram stain * Woman and her male partner both interested in study participation * Woman able to return for follow-up visits * Woman able to provide detailed contact information for tracing

Exclusion criteria

* Either male or female partner not recruited within 24 hours of the other

Design outcomes

Primary

MeasureTime frame
bacterial vaginosis by Nugent's scoreup to 2 months following treatment

Secondary

MeasureTime frame
presence of lactobacillus by culture2 months following treatment

Countries

Kenya

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026